Current FDA Status
- Phase 3 trials complete: Eli Lilly has finished nearly all Phase 3 studies of orforglipron, a once-daily oral GLP-1 receptor agonist for obesity and type 2 diabetes
- NDA (New Drug Application) submission: Complete; FDA reviewed it under its National Priority Voucher pilot
- FDA decision: Approved as Foundayo on April 1, 2026 for chronic weight management in adults with obesity, or overweight with at least one weight-related condition
All major clinical trials finished
Application filing to FDA
National Priority Voucher pilot
FDA-approved as Foundayo
Phase 3 Trial Results
In Phase 3 trials:
- In the ATTAIN-2 trial (adults with overweight/obesity plus type 2 diabetes), participants on the highest dose (~36 mg) lost on average ~10.5% of body weight (~22.9 lbs) versus ~2.2% with placebo.[1][4]
- In the ACHIEVE-1 trial (type 2 diabetes population), A1C reductions averaged ~1.3-1.6% from ~8.0% baseline; weight loss at the highest dose was ~7.9% (~16 lbs) at ~40 weeks.[4]
- Side effects seen have been consistent with the GLP-1 class: mostly gastrointestinal (nausea, vomiting, diarrhea), generally mild-to-moderate.[4]
Development Timeline
To better understand where orforglipron stands today, here's a look at the key development milestones the drug has passed through:
| Phase | Status | Timeframe | Description |
|---|---|---|---|
| Phase 1 (Safety & Dosing) | ✓ Complete | ~2019–2020 | Early small studies to verify safety, dose range |
| Phase 2 (Proof-of-Concept) | ✓ Complete | ~2021–2022 | Mid-sized trials, type 2 diabetes efficacy |
| Phase 3 (Pivotal) | ✓ Complete | ~2023–2025 | Large global studies in obesity & diabetes |
| Extension Studies | ⟳ Ongoing | 2025–2026 | Long-term safety follow-up (not required for NDA) |
| NDA Submission (Obesity) | ✓ Complete | Late 2025 | Formal filing for regulatory approval |
| NDA Submission (Diabetes) | ⊙ Planned | 2026 | Separate filing for type 2 diabetes indication |
| FDA Review & Decision | ✓ Approved | April 1, 2026 | Approved as Foundayo for chronic weight management |
Summary for Readers: Drug development moves through three major phases—small safety tests, mid-size efficacy trials, and large pivotal studies—before a company files an NDA. Orforglipron completed every step, and the FDA approved it as Foundayo on April 1, 2026.
Approval Milestones
| Milestone | Date | Status | Details |
|---|---|---|---|
| Phase 1 Completion | November 2020 | ✓ Complete | Safety and dosing established |
| Phase 2 Completion | September 2022 | ✓ Complete | Proof-of-concept demonstrated |
| ACHIEVE-1 Results | April 2025 | ✓ Complete | First Phase 3 diabetes trial |
| ATTAIN-2 Results | August 2025 | ✓ Complete | Major obesity study |
| ACHIEVE-2 Results | October 2025 | ✓ Complete | Additional diabetes efficacy data |
| ACHIEVE-3 Results | September 2025 | ✓ Complete | Head-to-head vs oral semaglutide |
| ACHIEVE-4 Results | Early 2026 | ⟳ Ongoing | Final Phase 3 trial |
| NDA Submission (Obesity) | Late 2025 | ✓ Complete | Filing to FDA |
| NDA Submission (Diabetes) | 2026 | ⊙ Planned | Separate application |
| FDA Acceptance for Review | After submission | ✓ Complete | Agency confirmed completeness |
| Expedited Review | After acceptance | ✓ Complete | Reviewed under the National Priority Voucher pilot |
| FDA Decision (Obesity) | April 1, 2026 | ✓ Approved | Approved as Foundayo |
| Commercial Launch | 2026 | ✓ Available | Available by prescription as Foundayo |
Summary for Readers: The Phase 3 program supported the FDA submission, the FDA reviewed it under its National Priority Voucher pilot, and it approved orforglipron as Foundayo on April 1, 2026.
Approval Predictions
Update: These scenarios were written before the FDA decision and are kept for reference. The FDA approved orforglipron as Foundayo on April 1, 2026, under its National Priority Voucher pilot.
Best-Case Scenario
Timeline: Mid-2026 approval
What would need to happen:
- Early submission (Oct 2025)
- Acceptance into voucher/expedited pathway
- Flawless review
- Clean manufacturing inspection
Most Likely Scenario
Timeline: Late 2026 / early 2027 approval
Assumptions:
- NDA in Q4 2025
- Standard review (~10-12 months)
- No major FDA questions
Delayed Scenario
Timeline: 2027 or later
Potential causes:
- FDA requests more safety data (e.g., cardiovascular outcomes)
- Manufacturing/quality issues
- Delayed submission
Historical Comparison: Similar Drug Approvals
| Drug | Developer | Indication | NDA to Approval | Notes |
|---|---|---|---|---|
| Oral Semaglutide (Rybelsus) | Novo Nordisk | Type 2 Diabetes | ~12 months | First oral GLP-1; approved 2019 |
| Tirzepatide (Zepbound) | Eli Lilly | Obesity | ~6 months (priority) | Priority review granted; approved 2023 |
| Semaglutide (Wegovy) | Novo Nordisk | Obesity | ~7 months (priority) | Priority review granted; approved 2021 |
Historical context: Metabolic Innovations for obesity/diabetes have sometimes received priority review (e.g., injectable agents). If orforglipron qualifies, review could accelerate significantly.
Summary for Readers: Most new metabolic drugs take about one year from submission to approval. A faster decision is possible if the FDA grants Priority Review; significant delays are uncommon for companies with Lilly's track record.
FDA Approval Process
After Eli Lilly submitted its New Drug Application (NDA), orforglipron moved through a structured FDA review process, ending in approval as Foundayo. Here's what that journey looks like:
NDA Submission
Eli Lilly submits a complete application package containing all clinical trial data, manufacturing details, proposed labeling, and safety plans.
FDA Filing Decision
FDA reviews the application for completeness. If accepted, they assign a PDUFA date (the target decision deadline) and determine if it qualifies for Priority Review (6 months) or Standard Review (10-12 months).
FDA Review Period
FDA scientists evaluate safety, efficacy, manufacturing quality, and labeling. They may request additional data or schedule an advisory committee meeting if needed.
PDUFA Date Decision
By the PDUFA date, the FDA must issue one of three decisions:
- Approval: Drug can be marketed
- Complete Response Letter: Issues need to be addressed before approval
- Extend review: More time needed (rare)
Summary for Readers: The FDA approval process typically takes 6-12 months after submission. The journey moves through four key stages: submission, filing acceptance, detailed review, and final decision. Special designations can significantly accelerate this timeline.
Post-Approval Rollout
After Approval:
- 1-3 months - Commercial launch begins: Product stocked in pharmacies/distributors
- 3-6 months - Insurers evaluate the therapy: Formulary inclusion decisions; patient access expands
- 6-12 months - Broader insurance coverage: Patient-assistance programs may be introduced
If Delayed or Not Approved:
- The FDA could issue a Complete Response Letter (CRL) requesting more data or highlighting manufacturing/safety issues
- Additional long-term safety or cardiovascular outcome studies might be required (common in weight-loss drugs)
- The company may resubmit, adding months to years of delay
Summary for Readers: After FDA approval, most drugs reach pharmacies within a few months. Insurance coverage often follows within half a year as payers complete formulary reviews.
FAQs
It already is. The FDA approved orforglipron as Foundayo on April 1, 2026 for chronic weight management in adults with obesity, or overweight with at least one weight-related condition. The FDA reviewed it under its Commissioner's National Priority Voucher pilot.
Yes. Orforglipron is FDA-approved as Foundayo (April 1, 2026) and available by prescription. Clinical trials remain an option for uses that are not yet approved. You can search for active trials at ClinicalTrials.gov by searching "orforglipron" or "LY3502970."
The PDUFA date (Prescription Drug User Fee Act date) is the FDA's target deadline for completing its review of the NDA. It's typically set approximately 60 days after the FDA accepts the NDA for filing. Orforglipron's review is complete: the FDA approved it as Foundayo on April 1, 2026.
The Commissioner's National Priority Voucher is a new FDA pilot program that allows expedited review (1-2 months) for drugs treating high-burden chronic conditions that meet certain criteria. Orforglipron was reviewed under this program: the FDA says Foundayo was the first new molecular entity approved under the National Priority Voucher pilot.
Insurance coverage will depend on several factors: FDA-approved indications (obesity vs diabetes), payer formulary decisions, and prior authorization requirements. Based on current GLP-1 coverage patterns, we expect:
- Type 2 Diabetes: Broader coverage, as diabetes is widely covered by most insurers
- Obesity: More variable coverage; some insurers exclude obesity medications entirely, while others cover them with strict criteria (e.g., BMI ≥30 or ≥27 with comorbidity)
Now that it is approved as Foundayo, check your plan's formulary. Medicare Part D enrollees may be able to get Foundayo for weight loss for $50 per monthly fill through the Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027), if they meet CMS's eligibility criteria.
Recent GLP-1 approvals have varied based on priority review status:
- Oral semaglutide (Rybelsus): ~12 months (standard review, diabetes indication, 2019)
- Semaglutide (Wegovy): ~7 months (priority review, obesity indication, 2021)
- Tirzepatide (Zepbound): ~6 months (priority review, obesity indication, 2023)
Orforglipron was reviewed under the FDA's National Priority Voucher pilot and approved as Foundayo on April 1, 2026.
Common reasons for approval delays include:
- Additional safety data requests: The FDA may want longer-term follow-up or cardiovascular outcomes data
- Manufacturing issues: Problems identified during FDA facility inspections
- Complete Response Letter (CRL): FDA's formal notification that the application is not ready for approval, requiring resubmission
- Advisory committee meeting: The FDA may convene an external expert panel to review the data, which can add 3-6 months to the timeline
For orforglipron's weight-management use, this is now history: the FDA approved it as Foundayo on April 1, 2026.
Not at the same time. The FDA approved orforglipron as Foundayo for chronic weight management on April 1, 2026; type 2 diabetes is a separate indication that needs its own FDA review and approval. This is similar to how semaglutide was approved: first for diabetes (Ozempic, 2017), then for obesity (Wegovy, 2021). Each indication requires separate FDA review and approval. If both are approved, orforglipron would be marketed with different labeling and potentially different dosing for each indication.
Sources & References
- Eli Lilly and Company. "Lilly to Submit Obesity Pill After Hitting Goal in Third Late-Stage Trial." Press Release, August 26, 2025. https://investor.lilly.com/news-releases
- Pratt E, Ma X, Compean S, et al. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes. Diabetes Obes Metab. 2023;25(9):2513-2523. https://pubmed.ncbi.nlm.nih.gov/37264711/
- Frias JP, Hsia S, Eyde S, et al. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet. 2023;402(10403):472-483. https://pubmed.ncbi.nlm.nih.gov/37369232/
- Eli Lilly and Company. "Lilly's Oral GLP-1, Orforglipron, Demonstrated Statistically Significant Efficacy Results and a Safety Profile Consistent with Injectable GLP-1 Medicines in Successful Phase 3 Trial." Press Release, April 17, 2025. https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-demonstrated-statistically
- Pharmaceutical Executive. "Lilly's Orforglipron Considered 'Prime Candidate' for New FDA Fast Track Approval Program." Report, 2025. https://www.pharmexec.com/view/lilly-orforglipron-prime-candidate-fda-fast-track-approval-program-report
- Clinical Trials Arena. "Eli Lilly Eyes Orforglipron Approval After Phase III Diabetes Trial Success." September 2025. https://www.clinicaltrialsarena.com/news/eli-lilly-eyes-orforglipron-approval-after-phase-iii-diabetes-trial-success/
- U.S. Food and Drug Administration. "Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review." https://www.fda.gov/patients/learn-about-drug-and-device-approvals/fast-track-breakthrough-therapy-accelerated-approval-priority-review
- ClinicalTrials.gov. "Search Results: Orforglipron." https://clinicaltrials.gov/search?term=orforglipron
Last updated October 6, 2026 · Key facts verified October 5, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.